SAB Biotherapeutics (SABS) Accumulated Depreciation (2020 - 2026)

SAB Biotherapeutics' Accumulated Depreciation history runs 7 years deep, the most recent figure standing at $18.1 million for Q1 2026.

• Quarterly Accumulated Depreciation rose 18.27% year-over-year to $18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (up 18.27% YoY) and the FY2025 annual result came in at $17.5 million, up 20.19% from the prior year.
• Accumulated Depreciation was $18.1 million for Q1 2026 at SAB Biotherapeutics, up from $17.5 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $18.1 million in Q1 2026 and bottomed at $3.8 million in Q1 2022.
• A 5-year average of $11.7 million and a median of $12.9 million in 2024 frame the typical range for Accumulated Depreciation.
• Annual changes were most pronounced in 2022 — Accumulated Depreciation soared 94.98% — and 2026, when it gained 18.27%.
• SAB Biotherapeutics' Accumulated Depreciation stood at $6.3 million in 2022, then jumped by 57.87% to $9.9 million in 2023, then soared by 47.04% to $14.6 million in 2024, then climbed by 20.19% to $17.5 million in 2025, then grew by 3.47% to $18.1 million in 2026.
• Business Quant data shows SABS's Accumulated Depreciation at $18.1 million in Q1 2026, $17.5 million in Q4 2025, and $16.8 million in Q3 2025.